Diovan HCT
These highlights do not include all the information needed to use DIOVAN HCT safely and effectively. See full prescribing information for DIOVAN HCT. DIOVAN HCT (valsartan and hydrochlorothiazide USP) tablets, for oral use Initial U.S. Approval: 1998
d76a0419-05ee-437e-884c-65807aea9569
HUMAN PRESCRIPTION DRUG LABEL
Jul 11, 2023
Novartis Pharmaceuticals Corporation
DUNS: 002147023
Products 5
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
valsartan and hydrochlorothiazide
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (11)
valsartan and hydrochlorothiazide
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (11)
valsartan and hydrochlorothiazide
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (11)
valsartan and hydrochlorothiazide
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (11)
valsartan and hydrochlorothiazide
Product Details
FDA regulatory identification and product classification information
